Belatacept: the challenges with transformational drugs

Affiliations

Comment

Flavio Vincenti. Transl Androl Urol. 2017 Apr.

. 2017 Apr;6(2):341-342.

doi: 10.21037/tau.2017.03.07.

¹ Transplant Center, University of California, San Francisco, San Francisco, CA 94143, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has received research grants from Bristol-Myers Squibb, Novartis and Genentech.

Belatacept in renal transplantation-quo vadis?
Westhoff TH. Westhoff TH. Transl Androl Urol. 2016 Dec;5(6):953-955. doi: 10.21037/tau.2016.11.11. Transl Androl Urol. 2016. PMID: 28078228 Free PMC article. No abstract available.

1. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012;12:210-7. 10.1111/j.1600-6143.2011.03785.x - DOI - PubMed
1. Ferguson R, Grinyó J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011;11:66-76. 10.1111/j.1600-6143.2010.03338.x - DOI - PubMed
1. Kirk AD, Guasch A, Xu H, et al. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant 2014;14:1142-51. 10.1111/ajt.12712 - DOI - PMC - PubMed
1. Lo DJ, Anderson DJ, Weaver TA, et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 2013;13:320-8. 10.1111/j.1600-6143.2012.04342.x - DOI - PMC - PubMed
1. Lowe MC, Badell IR, Turner AP, et al. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am J Transplant 2013;13:312-9. 10.1111/j.1600-6143.2012.04341.x - DOI - PMC - PubMed